tetano
Editor, Senior Moderator
Emerg Infect Dis. 2018 Jul 17;24(7). doi: 10.3201/eid2407.180028. [Epub ahead of print]
[h=1]Mapping of the US Domestic Influenza Virologic Surveillance Landscape.[/h] Jester B, Schwerzmann J, Mustaquim D, Aden T, Brammer L, Humes R, Shult P, Shahangian S, Gubareva L, Xu X, Miller J, Jernigan D.
[h=3]Abstract[/h] Influenza virologic surveillance is critical each season for tracking influenza circulation, following trends in antiviral drug resistance, detecting novel influenza infections in humans, and selecting viruses for use in annual seasonal vaccine production. We developed a framework and process map for characterizing the landscape of US influenza virologic surveillance into 5 tiers of influenza testing: outpatient settings (tier 1), inpatient settings and commercial laboratories (tier 2), state public health laboratories (tier 3), National Influenza Reference Center laboratories (tier 4), and Centers for Disease Control and Prevention laboratories (tier 5). During the 2015-16 season, the numbers of influenza tests directly contributing to virologic surveillance were 804,000 in tiers 1 and 2; 78,000 in tier 3; 2,800 in tier 4; and 3,400 in tier 5. With the release of the 2017 US Pandemic Influenza Plan, the proposed framework will support public health officials in modeling, surveillance, and pandemic planning and response.
[h=4]KEYWORDS:[/h] United States; diagnosis; fluorescent antibody technique; genetic sequence analysis; immunoassay; influenza; nucleic acid amplification techniques; pandemic planning; surveillance; vaccine virus selection; viruses
PMID: 29715078 DOI: 10.3201/eid2407.180028
Free full text
[h=1]Mapping of the US Domestic Influenza Virologic Surveillance Landscape.[/h] Jester B, Schwerzmann J, Mustaquim D, Aden T, Brammer L, Humes R, Shult P, Shahangian S, Gubareva L, Xu X, Miller J, Jernigan D.
[h=3]Abstract[/h] Influenza virologic surveillance is critical each season for tracking influenza circulation, following trends in antiviral drug resistance, detecting novel influenza infections in humans, and selecting viruses for use in annual seasonal vaccine production. We developed a framework and process map for characterizing the landscape of US influenza virologic surveillance into 5 tiers of influenza testing: outpatient settings (tier 1), inpatient settings and commercial laboratories (tier 2), state public health laboratories (tier 3), National Influenza Reference Center laboratories (tier 4), and Centers for Disease Control and Prevention laboratories (tier 5). During the 2015-16 season, the numbers of influenza tests directly contributing to virologic surveillance were 804,000 in tiers 1 and 2; 78,000 in tier 3; 2,800 in tier 4; and 3,400 in tier 5. With the release of the 2017 US Pandemic Influenza Plan, the proposed framework will support public health officials in modeling, surveillance, and pandemic planning and response.
[h=4]KEYWORDS:[/h] United States; diagnosis; fluorescent antibody technique; genetic sequence analysis; immunoassay; influenza; nucleic acid amplification techniques; pandemic planning; surveillance; vaccine virus selection; viruses
PMID: 29715078 DOI: 10.3201/eid2407.180028
Free full text